Purple Biotech’s Phase 2 pancreatic cancer study selected as presentation

Purple Biotech (PPBT) announced that interim results from its randomized, controlled, open label, multicenter Phase 2 study of CM24, a first in class immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma, have been selected as late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting which will take place on May 31 – June 4, 2024 in Chicago, Illinois. The Phase 2 study is evaluating CM24 in combination with the Bristol Myers Squibb (BMY) PD-1 inhibitor nivolumab plus standard of care chemotherapy in second line PDAC patients compared to SoC chemotherapy alone. The primary endpoint of the study is overall survival, with progression free survival and objective response rate as secondary endpoints. The study was designed as Bayesian to evaluate the potential benefit of the experimental arm vs SoC and is not powered for hypothesis testing. Approximately 60 patients have been enrolled in the randomized study in 18 centers in the U.S., Spain and Israel. The study is in clinical collaboration with BMS. Purple Biotech retains all worldwide rights to CM24.